drugset / Trial / NCT03992196

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

NCT03992196

Phase 3 Terminated 10 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).

Timeline

Start
2019-12-03
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 1 mg Other
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 3 mg Other